Next 10 |
home / stock / bhvn / bhvn articles
U.S. stocks were lower, with the Dow Jones index falling around 1% on Thursday. Shares of HP Inc. (NYSE:HPQ) rose sharply during Thursday's se...
Biohaven Ltd’s (NYSE:BHVN) shares are trading lower on Wednesday. The company reported new interim data from the ongoing Phase 1 study of BHV...
Biohaven Ltd. (NYSE:BHVN) stock is moving lower Wednesday. The company recently presented several updates in different fields such as immunology an...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidenc...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...
Wednesday, Altimmune Inc (NASDAQ:ALT) said the body composition study of pemvidutide showed lean mass preservation, with 25.5% of weight ...
Monday, Biohaven’s (NYSE:BHVN) CEO, Vlad Coric, joined CNBC Fast Money to discuss the weight loss drug wars and the company...
RBC Capital Markets has initiated Biohaven Ltd (NYSE:BHVN), noting optimized development across programs. The analyst highlight...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...
2024-05-29 11:00:21 ET Leonid Timashev from RBC Capital issued a price target of $59.00 for BHVN on 2024-05-29 09:14:00. The adjusted price target was set to $59.00. At the time of the announcement, BHVN was trading at $28.69. The overall price target consensus is at $23...